DekaBank Deutsche Girozentrale purchased a new stake in shares of Guardant Health Inc (NASDAQ:GH) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 14,000 shares of the company’s stock, valued at approximately $1,103,000.

A number of other institutional investors have also made changes to their positions in the business. FMR LLC increased its stake in Guardant Health by 28.3% during the 1st quarter. FMR LLC now owns 464,612 shares of the company’s stock worth $35,636,000 after purchasing an additional 102,483 shares in the last quarter. First Trust Advisors LP boosted its position in Guardant Health by 0.4% during the 1st quarter. First Trust Advisors LP now owns 71,871 shares of the company’s stock worth $5,513,000 after acquiring an additional 264 shares during the last quarter. Royal Bank of Canada boosted its position in Guardant Health by 41.2% during the 2nd quarter. Royal Bank of Canada now owns 8,561 shares of the company’s stock worth $739,000 after acquiring an additional 2,498 shares during the last quarter. Envestnet Asset Management Inc. acquired a new position in Guardant Health during the 3rd quarter worth approximately $260,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Guardant Health by 160.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,288 shares of the company’s stock worth $146,000 after acquiring an additional 1,408 shares during the last quarter. 78.53% of the stock is owned by institutional investors and hedge funds.

In other news, CFO Derek A. Bertocci sold 25,481 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $79.58, for a total value of $2,027,777.98. Following the completion of the sale, the chief financial officer now owns 99,684 shares of the company’s stock, valued at approximately $7,932,852.72. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Amirali Talasaz sold 62,587 shares of the stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $80.71, for a total value of $5,051,396.77. Following the completion of the sale, the chief operating officer now directly owns 71,951 shares of the company’s stock, valued at approximately $5,807,165.21. The disclosure for this sale can be found here. In the last three months, insiders sold 175,061 shares of company stock valued at $13,929,591. 13.00% of the stock is currently owned by insiders.

A number of equities analysts have weighed in on the company. ValuEngine downgraded Guardant Health from a “buy” rating to a “hold” rating in a research report on Tuesday, December 3rd. William Blair reaffirmed an “outperform” rating on shares of Guardant Health in a research report on Friday, November 8th. Zacks Investment Research raised Guardant Health from a “hold” rating to a “strong-buy” rating and set a $90.00 price target for the company in a research report on Wednesday, January 29th. Citigroup assumed coverage on Guardant Health in a research report on Monday, January 6th. They set a “buy” rating and a $100.00 price target for the company. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $125.00 price target on shares of Guardant Health in a research report on Friday, November 8th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $107.33.

NASDAQ:GH opened at $84.30 on Friday. Guardant Health Inc has a twelve month low of $49.25 and a twelve month high of $112.21. The business has a 50 day moving average price of $79.79 and a two-hundred day moving average price of $78.90. The company has a market cap of $7.68 billion, a P/E ratio of -96.90 and a beta of 0.23.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.

Read More: How Do You Calculate Return on Equity (ROE)?

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.